

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://FDILab.SciCrunch.org) on May 6, 2025

Brilliant Violet 421(TM) anti-human/mouse Granzyme B Recombinant

RRID:AB_2810603

Type: Antibody

Proper Citation

(BioLegend Cat# 396414, RRID:AB_2810603)

Antibody Information

URL: http://antibodyregistry.org/AB_2810603

Proper Citation: (BioLegend Cat# 396414, RRID:AB_2810603)

Target Antigen: Granzyme B

Host Organism: rat

Clonality: recombinant monoclonal

Comments: Applications: ICFC

Antibody Name: Brilliant Violet 421(TM) anti-human/mouse Granzyme B Recombinant

Description: This recombinant monoclonal targets Granzyme B

Target Organism: Human, Mouse

Clone ID: Clone QA18A28

Antibody ID: AB_2810603

Vendor: BioLegend

Catalog Number: 396414

Alternative Catalog Numbers: 396413

Record Creation Time: 20231110T032645+0000

Record Last Update: 20240725T061346+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-human/mouse Granzyme B Recombinant.

No alerts have been found for Brilliant Violet 421(TM) anti-human/mouse Granzyme B Recombinant.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Sun Y, et al. (2024) Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. Cancer cell, 42(1), 135.

Wang L, et al. (2024) Targeting the HSP47-collagen axis inhibits brain metastasis by reversing M2 microglial polarization and restoring anti-tumor immunity. Cell reports. Medicine, 5(5), 101533.

Hope JL, et al. (2023) PSGL-1 attenuates early TCR signaling to suppress CD8+ T cell progenitor differentiation and elicit terminal CD8+ T cell exhaustion. Cell reports, 42(5), 112436.

Lin YH, et al. (2023) Small intestine and colon tissue-resident memory CD8+ T cells exhibit molecular heterogeneity and differential dependence on Eomes. Immunity, 56(1), 207.

Wang F, et al. (2023) Targeting VCP potentiates immune checkpoint therapy for colorectal cancer. Cell reports, 42(11), 113318.

Yang QC, et al. (2023) Targeting PCSK9 reduces cancer cell stemness and enhances antitumor immunity in head and neck cancer. iScience, 26(6), 106916.

Shuwa HA, et al. (2021) Alterations in T and B cell function persist in convalescent COVID-19 patients. Med (New York, N.Y.), 2(6), 720.